Custom Knockout Cell Line Service: Strategy, Cloning and Triple Validation

Four stages, each with a defined output:

The strategy stage is where most outsourcing fails. A supplier who starts with "send us your gene" has skipped the decision that determines whether the project is two months or six.

Difficult loci, essential genes, and primary-like cells move to the upper end or require a modality change.

• • Gene, transcript, and the exon or region you want disrupted
• • Cell line, with source and passage if you are supplying it
• • Whether you need homozygous or heterozygous clones
• • The intended assay, so validation can be matched to it
• • Any prior guide or delivery data, including failures

• • Essential genes cannot be delivered as constitutive knockouts. We will propose inducible knockdown or degron lines instead.
• • Primary cells usually cannot be cloned; the deliverable becomes a validated pool.
• • Efficiency is locus- and cell-type-specific. We report pool-level editing before cloning, and advise whether the clone number is realistic.
• • We do not guarantee a phenotype. We guarantee the genotype, the protein data and the documentation.

Can you work with our line?Yes, with a receipt QC and a pilot edit. If the line proves uneditable, the pilot report explains why and what we recommend instead.

Do you provide the guides?Yes, with sequences and a design rationale, so the work is reproducible in your hands.

What if only one clone validates?We continue until two validate or the campaign is exhausted; if the latter, we report the allele spectrum and recommend a strategy change rather than delivering a single clone quietly.

Send the gene, the cell type and the intended assay. The first output is a written strategy — before any editing is scheduled.

Contact EDITGENE to request a project consultation or quote.

Timelines are planning ranges for established workflows and depend on locus, cell type, and delivery feasibility.

Validation confirms clones at the passage tested; documentation is provided so that results can be reproduced and audited.

• • Sentmanat MF, et al. A survey of validation strategies for CRISPR-Cas9 editing. Scientific Reports. 2018;8:888.
• • Doench JG, et al. Optimized sgRNA design to maximize activity and minimize off-target effects. Nature Biotechnology. 2016;34:184–191.
• • Geraghty RJ, et al. Guidelines for the use of cell lines in biomedical research. British Journal of Cancer. 2014;111:1021–1046.